Genus plc (GNS) Ordinary 10p

Sell:2,680.00pBuy:2,685.00p30.00p (1.10%)

FTSE techMARK 100:0.30%
Market closed |
Prices delayed by at least 15 minutes
Sell:2,680.00p
Buy:2,685.00p
Change:30.00p (1.10%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:2,680.00p
Buy:2,685.00p
Change:30.00p (1.10%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Genus plc is a United Kingdom-based global animal genetics company. The Company is advancing animal breeding and genetic improvement by applying biotechnology and selling added value products to livestock farming and food producers. It focuses on the dairy, beef and pork food production sectors, through two businesses: ABS (bovine genetics) and PIC (porcine genetics). Its segments include Genus PIC, Genus ABS and Genus Research and Development. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. Its porcine and bovine divisions operate under the brand names PIC and ABS. It operates in 30 countries, across six continents, and reaches a further 50 markets through distribution partners.

Key people

Jorgen Kokke
Chief Executive Officer, Executive Director
Andy Russell
Chief Financial Officer, Executive Director
Matt Culbertson
Chief Operating Officer
Angelle Rosata
Chief Human Resources Officer
Elena Rice
Chief Scientific Officer and Head of Research and Development
Dan Hartley
Group General Counsel and Company Secretary
Jim Low
Chief Operating Officer of Genus ABS
Jerry Thompson
Regional Director - ABS EMEA
Iain G. T. Ferguson
Non-Executive Independent Chairman of the Board
Lysanne Gray
Non-Executive Independent Director
Ralph Heuser
Non-Executive Independent Director
Lesley Mary Samuel Knox
Senior Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    GNS
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB0002074580
  • Market cap
    £1.76bn
  • Employees
    3,439
  • Shares in issue
    66.04m
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, Britain-FTSE250-Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.